• Return to Headlines

Shares of Vertex Pharm Rank the Highest in Terms of EV/EBITDA Ratio in the Biotechnology Industry (VRTX, GHDX, IONS, BMRN, RGEN)

By Shiri Gupta

Below are the three companies in the Biotechnology industry with the highest enterprise value to EBITDA (EV/EBITDA) ratios. EV/EBITDA is an important metric used in valuing comparable companies. It is capital structure neutral and generally the lower the ratio, the more undervalued the company is believed to be.

Vertex Pharm ranks highest with a an EV/EBITDA ratio of 1,193.49. Following is Genomic Health I with a an EV/EBITDA ratio of 470.62. Ionis Pharmaceut ranks third highest with a an EV/EBITDA ratio of 429.07.

Biomarin Pharmac follows with a an EV/EBITDA ratio of 253.94, and Repligen Corp rounds out the top five with a an EV/EBITDA ratio of 137.23.

SmarTrend recommended that its subscribers protect gains by selling shares of Genomic Health I on September 27th, 2019 by issuing a Downtrend alert when the shares were trading at $69.60. Since that call, shares of Genomic Health I have fallen 8.9%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.

Keywords: highest ev/ebitda ratio vertex pharm genomic health i ionis pharmaceut biomarin pharmac repligen corp

Ticker(s): VRTX GHDX IONS BMRN RGEN